Transgene Transgene leaped Exchange after the results of a treatment against lung cancer
Transgene started 2014 in the best way it is . The biotechnology company announced encouraging results from the Phase 2b study of TG4010 , a treatment against lung cancer . Transgene now considering the initiation of Phase 3 of the study.Analysis ( Investing )
Transgene is festive Exchange. The action of this biotech company won up to 17% in mid-morning to hit 11 euros sounds spot , its highest level since April 2012. All in a volume of transactions particularly rich : 450,000 shares have been treated since the opening ...
Which raises the enthusiasm of the market : the presentation of preliminary results of the Phase 2b TG4010 , a therapeutic vaccine (not preventive) against lung cancer " non-small cell " in the metastatic phase , especially the announcement of a Phase 3 can . " In 75 % of patients with values TrPAL [ TrPAL biomarker measurement before treatment, the blood level of triple - positive lymphocytes , ed] the lowest and having received TG4010 combination - chemotherapy, there was a significant improvement over medical plan PFS " without disease , says biotech , 55% owned by the Mérieux family. The risk of aggravation of the tumor or death is reduced by more than 25%. Better yet, it seems that a new stratification of patients could be performed. Analyzes of subgroups show that improved progression-free survival was more pronounced among people with cancer and non-squamous lung had not received bevacizumab (Avastin ) Roche laboratory .Biotech could collect 700 million euros
Given these results, Novartis may exercise its option giving it the right to develop and commercialize ( through royalties) product exclusively. This opens the door to a windfall of € 700 million. Biotech will also seek authorization to conduct the Phase 3 trial , also called " pivot " before approval to market a drug.
TG4010 has a huge potential to exceed a billion euros in turnover. In fact, lung cancer is one of the most widespread in the world, making 1.6 million new victims each year. The " non-small cell " represents about 80 % of cases of lung cance
Transgene started 2014 in the best way it is . The biotechnology company announced encouraging results from the Phase 2b study of TG4010 , a treatment against lung cancer . Transgene now considering the initiation of Phase 3 of the study.Analysis ( Investing )
Transgene is festive Exchange. The action of this biotech company won up to 17% in mid-morning to hit 11 euros sounds spot , its highest level since April 2012. All in a volume of transactions particularly rich : 450,000 shares have been treated since the opening ...
Which raises the enthusiasm of the market : the presentation of preliminary results of the Phase 2b TG4010 , a therapeutic vaccine (not preventive) against lung cancer " non-small cell " in the metastatic phase , especially the announcement of a Phase 3 can . " In 75 % of patients with values TrPAL [ TrPAL biomarker measurement before treatment, the blood level of triple - positive lymphocytes , ed] the lowest and having received TG4010 combination - chemotherapy, there was a significant improvement over medical plan PFS " without disease , says biotech , 55% owned by the Mérieux family. The risk of aggravation of the tumor or death is reduced by more than 25%. Better yet, it seems that a new stratification of patients could be performed. Analyzes of subgroups show that improved progression-free survival was more pronounced among people with cancer and non-squamous lung had not received bevacizumab (Avastin ) Roche laboratory .Biotech could collect 700 million euros
Given these results, Novartis may exercise its option giving it the right to develop and commercialize ( through royalties) product exclusively. This opens the door to a windfall of € 700 million. Biotech will also seek authorization to conduct the Phase 3 trial , also called " pivot " before approval to market a drug.
TG4010 has a huge potential to exceed a billion euros in turnover. In fact, lung cancer is one of the most widespread in the world, making 1.6 million new victims each year. The " non-small cell " represents about 80 % of cases of lung cance
0 comments:
Post a Comment